Hyloris Pharmaceuticals SA (HYL.BR)

EUR 5.83

(0.34%)

Operating Expenses Summary of Hyloris Pharmaceuticals SA

  • Hyloris Pharmaceuticals SA's latest annual operating expenses in 2023 was 17.98 Million EUR , up 46.79% from previous year.
  • Hyloris Pharmaceuticals SA's latest quarterly operating expenses in 2023 FY was 19.61 Million EUR , up 46.79% from previous quarter.
  • Hyloris Pharmaceuticals SA reported a annual operating expenses of 13.36 Million EUR in annual operating expenses 2022, up 0.21% from previous year.
  • Hyloris Pharmaceuticals SA reported a annual operating expenses of 13.33 Million EUR in annual operating expenses 2021, up 137.86% from previous year.
  • Hyloris Pharmaceuticals SA reported a quarterly operating expenses of 6.05 Million EUR for 2023 Q3, up 47.36% from previous quarter.
  • Hyloris Pharmaceuticals SA reported a quarterly operating expenses of 4.1 Million EUR for 2023 Q1, up 0.23% from previous quarter.

Annual Operating Expenses Chart of Hyloris Pharmaceuticals SA (2023 - 2017)

Historical Annual Operating Expenses of Hyloris Pharmaceuticals SA (2023 - 2017)

Year Operating Expenses Operating Expenses Growth
2023 17.98 Million EUR 46.79%
2022 13.36 Million EUR 0.21%
2021 13.33 Million EUR 137.86%
2020 5.6 Million EUR 5.81%
2019 5.29 Million EUR -3.57%
2018 5.49 Million EUR 37.96%
2017 3.98 Million EUR 0.0%

Peer Operating Expenses Comparison of Hyloris Pharmaceuticals SA

Name Operating Expenses Operating Expenses Difference
Nicox S.A. -11.5 Million EUR 256.368%
European Medical Solutions 13.64 Million EUR -31.802%
FERMENTALG 12.34 Million EUR -45.715%
argenx SE 1.34 Billion EUR 98.66%
BioSenic S.A. 7.58 Million EUR -137.202%
Celyad Oncology SA 8.49 Million EUR -111.861%
Onward Medical N.V. 20.64 Million EUR 12.875%
Oxurion NV 12.21 Million EUR -47.265%
PHAXIAM Therapeutics S.A. 24.98 Million EUR 28.012%
Financière de Tubize SA 114.38 Thousand EUR -15624.414%
UCB SA 2.94 Billion EUR 99.388%